Business Wire News with Multimedia: Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Business Wire News with Multimedia News with Multimedia distributed by Business Wire

Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression Jun 29th 2013, 01:20 MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Announces FDA Approval of Latuda® (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression Media files: Sunovion_LogoTagline.jpg (image/jpeg, 0 MB)

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions